DE69728710D1 - Eine pharmazeutische Tablette charakterisiert durch hohen Volumenzuwachs bei Kontakt mit biologischen Flüssigkeiten - Google Patents

Eine pharmazeutische Tablette charakterisiert durch hohen Volumenzuwachs bei Kontakt mit biologischen Flüssigkeiten

Info

Publication number
DE69728710D1
DE69728710D1 DE69728710T DE69728710T DE69728710D1 DE 69728710 D1 DE69728710 D1 DE 69728710D1 DE 69728710 T DE69728710 T DE 69728710T DE 69728710 T DE69728710 T DE 69728710T DE 69728710 D1 DE69728710 D1 DE 69728710D1
Authority
DE
Germany
Prior art keywords
contact
high volume
volume increase
pharmaceutical form
pharmaceutical tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69728710T
Other languages
English (en)
Other versions
DE69728710T2 (de
Inventor
Ubaldo Conte
Lauretta Maggi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec AG filed Critical Jagotec AG
Publication of DE69728710D1 publication Critical patent/DE69728710D1/de
Application granted granted Critical
Publication of DE69728710T2 publication Critical patent/DE69728710T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
DE69728710T 1996-02-19 1997-02-18 Eine pharmazeutische Tablette charakterisiert durch hohen Volumenzuwachs bei Kontakt mit biologischen Flüssigkeiten Expired - Lifetime DE69728710T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT96MI000311A IT1282650B1 (it) 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
ITMI960311 1996-02-19

Publications (2)

Publication Number Publication Date
DE69728710D1 true DE69728710D1 (de) 2004-05-27
DE69728710T2 DE69728710T2 (de) 2005-04-07

Family

ID=11373320

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69728710T Expired - Lifetime DE69728710T2 (de) 1996-02-19 1997-02-18 Eine pharmazeutische Tablette charakterisiert durch hohen Volumenzuwachs bei Kontakt mit biologischen Flüssigkeiten

Country Status (12)

Country Link
US (1) US5780057A (de)
EP (2) EP0795324B1 (de)
JP (1) JP3251190B2 (de)
AT (2) ATE264670T1 (de)
AU (1) AU719170B2 (de)
CA (1) CA2197941C (de)
DE (1) DE69728710T2 (de)
DK (1) DK0795324T3 (de)
ES (2) ES2376199T3 (de)
IT (1) IT1282650B1 (de)
NZ (1) NZ314265A (de)
PT (1) PT795324E (de)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US5804165A (en) * 1996-07-24 1998-09-08 Arnold; Michael J. Antiplaque oral composition
DE19640062B4 (de) * 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
IN186245B (de) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
DE69812094T2 (de) * 1997-12-22 2003-12-24 Schering Corp Feste, oral verabreichbare ribavirin dosisformen und verfahren zu deren herstellung
DE69925269T2 (de) * 1998-06-05 2006-02-23 Warner-Lambert Co. Llc Stabilisierung von zusammensetzungen enthaltend ace-hemmer durch magnesiumoxid
KR20010075370A (ko) * 1998-09-25 2001-08-09 낸시 엠. 그레이 경구 투여용 액상 약제
US6416786B1 (en) 1998-12-11 2002-07-09 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
MY121470A (en) * 1999-05-03 2006-01-28 Ranbaxy Lab Ltd Stable solid pharmaceutical compositions containing enalapril maleate
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
FR2797185B1 (fr) * 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
JP4565456B2 (ja) * 1999-11-02 2010-10-20 塩野義製薬株式会社 着色顆粒の色素定着法
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
CA2412490A1 (en) * 2000-06-23 2002-01-03 Moshe Fleshner-Barak Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US20060099245A1 (en) * 2000-08-01 2006-05-11 Manoj Kumar Hydrodynamically balancing oral drug delivery system with biphasic release
WO2002043694A2 (en) 2000-11-28 2002-06-06 Fmc Corporation Edible pga(propylene glycol alginate) coating composition
JP2004513975A (ja) * 2000-12-05 2004-05-13 マクグレゴール　アレキサンダー 作用物質の制御放出のための静水圧デリバリシステム
KR100685945B1 (ko) 2000-12-29 2007-02-23 엘지.필립스 엘시디 주식회사 액정표시장치 및 그 제조방법
US8268333B2 (en) * 2001-04-24 2012-09-18 Lintec Corporation Orally administered agent and an orally administered agent/supporting substrate complex
DE10120092B4 (de) * 2001-04-25 2008-03-20 Lts Lohmann Therapie-Systeme Ag Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
IL159812A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
AU2002340470A1 (en) 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US20030135065A1 (en) * 2001-11-13 2003-07-17 Ramy Lidor-Hadas Process for the production of L-DOPA ethyl ester
ATE290387T1 (de) * 2001-12-21 2005-03-15 Biopartners Gmbh Ribavirin-granulat zur herstellung von filmtabletten
KR20030056474A (ko) * 2001-12-28 2003-07-04 한국유나이티드제약 주식회사 카르비도파/레보도파 서방정의 조성물과 그의 제조방법
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US7008979B2 (en) * 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
PT1551372T (pt) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US20040091538A1 (en) * 2002-10-31 2004-05-13 Crystal Pollock-Dove Dosage form providing ascending release of liquid formulation
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
CA2550023C (en) 2003-12-16 2011-04-12 Cnsbio Pty Ltd Treatment of neuropathic pain
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2005084703A1 (ja) * 2004-03-09 2005-09-15 Nrl Pharma, Inc. 徐放性の口腔用組成物
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US9308176B2 (en) * 2004-10-15 2016-04-12 Supernus Pharmaceuticals, Inc Less abusable pharmaceutical preparations
KR20130115401A (ko) * 2004-11-19 2013-10-21 글락소스미스클라인 엘엘씨 약제학적 제품
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
EP1830886B1 (de) * 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Verfahren zur stabilisierung eines arzneimittels gegen demenz
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
MX2008000084A (es) * 2005-06-29 2008-03-18 Panacea Biotec Ltd Composiciones farmaceuticas de liberacion sostenida y procedimientos de las mismas.
CA2616416A1 (en) * 2005-09-09 2007-05-03 Labopharm, Inc. Trazodone composition for once a day adminisitiation
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007072495A2 (en) * 2005-11-03 2007-06-28 Sun Pharmaceutical Industries Limited Coated tablets having prolonged gastric retention
EP1945188A2 (de) * 2005-11-07 2008-07-23 Teva Pharmaceutical Industries Ltd. Levodopa-zusammensetzung
US7674396B2 (en) * 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
KR100752417B1 (ko) * 2006-02-14 2007-08-28 대원제약주식회사 안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
CN101484165A (zh) * 2006-05-03 2009-07-15 Cns生物有限公司 治疗炎性疼痛的方法与组合物
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
PL2526932T3 (pl) 2006-06-19 2017-12-29 Alpharma Pharmaceuticals Llc Kompozycja farmaceutyczna
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
EP2063872B2 (de) * 2006-08-30 2019-12-04 Jagotec AG Einen kern und eine oder mehrere barriereschichten enthaltende orale dosierformen mit kontrollierter freisetzung
EP2067475A4 (de) * 2006-09-26 2010-12-15 Astellas Pharma Inc Tacrolimus-zubereitung mit verzögerter freisetzung
WO2008039193A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
EP2066303B1 (de) * 2006-09-26 2016-05-04 Plensat, LLC System zur behandlung von essstörungen
EP1935411A1 (de) 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Langsam freisetzender Hilfsstoff und seine Verwendung
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
AT505225A1 (de) 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
KR20110025833A (ko) * 2008-06-16 2011-03-11 아피언 랍스, 엘엘씨 활성제의 일정한 (0-차) 방출을 위한 방출 시스템의 조성물 및 제조방법
WO2010019915A1 (en) * 2008-08-15 2010-02-18 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
AU2009301994B2 (en) 2008-10-08 2016-10-20 Bioplus Life Sciences Pvt. Ltd. Sustained release drug delivery system
WO2010048478A2 (en) * 2008-10-23 2010-04-29 Appian Labs, Llc Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
EP2210585A1 (de) 2009-01-16 2010-07-28 Exelgyn Pharmazeutische SPRM-Zusammensetzungen, Behandlungsverfahren unter Anwendung dieser
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US10485770B2 (en) 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
JP5459670B2 (ja) * 2010-05-07 2014-04-02 塩野義製薬株式会社 着色顆粒の色素定着化剤
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP2806861A1 (de) 2012-01-23 2014-12-03 Ranbaxy Laboratories Limited In-situ-mehrschichttablettentechnologie
US10166207B2 (en) 2013-06-05 2019-01-01 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
KR20170015389A (ko) 2014-06-02 2017-02-08 테바 파마슈티컬 인더스트리즈 리미티드 확장 가능한 위체류 투여 형태
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
US10363288B2 (en) 2015-01-14 2019-07-30 National Jewish Health Insulin mimotopes and methods of using the same
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
EP3432877B1 (de) 2016-03-24 2023-01-11 ImmunoMolecular Therapeutics, Inc. D-alpha-methyldopa zur behandlung von autoimmunerkrankungen
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3547974B1 (de) 2016-12-02 2023-11-15 Clexio Biosciences Ltd. Magenverweilsystem
KR102039345B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
TWI815832B (zh) 2017-12-01 2023-09-21 美商奧特吉尼克斯製藥公司 肌酸前藥、其組合物及使用方法
WO2019111132A1 (en) 2017-12-04 2019-06-13 Clexio Biosciences Ltd. Long acting gastric residence system
WO2019126218A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
EP3737353A1 (de) 2017-12-18 2020-11-18 Tris Pharma, Inc. Pharmazeutische ghb-zusammensetzungen mit einem system zur formung von schwimmenden interpenetrierenden polymernetzwerken
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN115844894A (zh) * 2018-05-15 2023-03-28 江苏豪森药业集团有限公司 包含第三代小分子egfr抑制剂的药物组合物及其制备方法
CN110214860A (zh) * 2019-07-10 2019-09-10 聂刘明 一种宠物饲料及其制备工艺
CA3226223A1 (en) * 2021-07-30 2023-02-02 Jacob Pade Ramsoe Jacobsen 5-hydroxytryptophan gastroretentive dosage forms
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
WO2023214018A1 (en) 2022-05-06 2023-11-09 Galenix Innovations Gastro-retentive swellable sustained release composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4839171A (en) * 1984-11-30 1989-06-13 Techmix, Inc. Composition for treating impaired lactation
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
JPH0747534B2 (ja) * 1986-06-02 1995-05-24 ロ−ラ−ジヤパン株式会社 錠 剤
US4869908A (en) * 1987-01-09 1989-09-26 K.V. Pharmaceutical Co. Fibre formulations
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time

Also Published As

Publication number Publication date
PT795324E (pt) 2004-09-30
ITMI960311A1 (it) 1997-08-19
ES2376199T8 (es) 2012-04-04
ATE530173T1 (de) 2011-11-15
AU719170B2 (en) 2000-05-04
ATE264670T1 (de) 2004-05-15
JPH09316005A (ja) 1997-12-09
EP0795324A3 (de) 1998-11-04
EP0795324B1 (de) 2004-04-21
EP0795324A2 (de) 1997-09-17
US5780057A (en) 1998-07-14
EP1382331A1 (de) 2004-01-21
NZ314265A (en) 1997-07-27
DK0795324T3 (da) 2004-08-16
ES2376199T3 (es) 2012-03-09
JP3251190B2 (ja) 2002-01-28
IT1282650B1 (it) 1998-03-31
CA2197941A1 (en) 1997-08-20
DE69728710T2 (de) 2005-04-07
ES2219709T3 (es) 2004-12-01
CA2197941C (en) 2001-12-04
ITMI960311A0 (de) 1996-02-19
EP1382331B1 (de) 2011-10-26
AU1477697A (en) 1997-08-28

Similar Documents

Publication Publication Date Title
ATE530173T1 (de) Eine pharmazeutische tablette charakterisiert durch hohen volumenzuwachs bei kontakt mit biologischen flüssigkeiten
ATE173159T1 (de) Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
ATE205705T1 (de) Arzneimittel zum wirkstoff - targetting in den dickdarm
FI924247A0 (fi) En doseringsform foer frigoerande av medicin till tarmen.
KR900015716A (ko) 거품이 이는 씹을 수 있는 정제 및 그의 제조방법 및 사용
KR880013586A (ko) 고체상태성질을 가진 제거 가능한 기질을 포함하는 투약기
KR880002502A (ko) 산에 민감한 유익한 약제의 투여용 제형(劑形)
MXPA99001958A (es) Tableta con liberacion controlada de clorhidrato de alfuzosina.
WO2001037812A3 (en) Gastroretentive controlled release pharmaceutical dosage forms
RU93058536A (ru) Орально вводимая форма лекарственного средства на основе пантопразола
ATE129404T1 (de) Dosierungsform fuer die freisetzung eines witkstoffs in einem kurzen zeitraum.
ATE264666T1 (de) Im magen verweilendes arzneimittel mit verzögerter wirkstoffabgabe
AU2001227915A1 (en) Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
DE60225481D1 (de) Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung
ATE304844T1 (de) Entzündungshemmende pharmazeutische formulierungen
ES2149341T3 (es) Expulsion de un material a partir de un dispositivo de liberacion.
Wilson The organization of the gut and the oral absorption of drugs: Anatomical, biological and physiological considerations in oral formulation development
Elperin et al. A patient's guide to protease inhibitors
PN et al. Approaches of Chronotherapeutic Drug Delivery Systems and Its Impact on Circadian Rhythm.
Pelfrene et al. The effect of cimetidine versus ranitidine on the gastric emptying rate of intensive care unit patients sustained on artificial respiration
Fonken Tips for taking Norvir (Ritonavir) oral solution
ITMI960310A1 (it) Portacravatte ad elementi modulari componibili
TH52797A (th) รูปแบบการบริหารยาโดยการรับประทาน
RU99127981A (ru) Способ лечения рецидивирующего фурункулеза
RU99113791A (ru) Способ инфузии лекарственных препаратов при несформированных наружных кишечных свищах

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MEISSNER, BOLTE & PARTNER GBR, 80538 MUENCHEN